Publication Topic : Access to Medicines

Global Access to Medicines: Will Canada Meet the Challenge? – Supplementary submission to the Standing Committee on Industry, Science and Technology regarding Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act

The Standing Committee has asked that we provide our views regarding the “alternatives” to the right of refusal that have been put forward by other witnesses appearing before the Committee. We address several of the most important points that have been put before the Committee.

Global Access to Medicines: Will Canada Meet the Challenge? – A Submission to the Standing Committee on Industry, Science and Technology regarding Bill C-9, An Act to amend the Patent Act and the Food and Drugs Act

Bill C-9 is Canada’s legislation to implement the WTO General Council Decision of 30 August 2003. The bill, therefore, should fully reflect the flexibility that the WTO Decision creates for countries to use compulsory licensing to import cheaper, generic phramaceutical products.

TRIPS from Doha to Cancún . . . to Ottawa: global developments in access to treatment and Canada’s Bill C-56 — HIV/AIDS Policy & Law Review 8(3)

In November 2003, Canada introduced legislation to amend the Patent Act so that manufacturers could obtain licences to make generic versions of patented pharmaceutical products for export to countries lacking sufficient capacity to produce their own. This article provides an overview of recent global developments leading up to Canada’s initiative, as well as an analysis … Read more